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Abstract
Membrane-associated RING-CH (MARCH) proteins represent a family of transmembrane ubiquitin ligases modulating
intracellular trafficking and turnover of transmembrane protein targets. While homologous proteins encoded by gamma-2
herpesviruses and leporipoxviruses have been studied extensively, limited information is available regarding the
physiological targets of cellular MARCH proteins. To identify host cell proteins targeted by the human MARCH-VIII ubiquitin
ligase we used stable isotope labeling of amino-acids in cell culture (SILAC) to monitor MARCH-dependent changes in the
membrane proteomes of human fibroblasts. Unexpectedly, we observed that MARCH-VIII reduced the surface expression of
Bap31, a chaperone that predominantly resides in the endoplasmic reticulum (ER). We demonstrate that Bap31 associates
with the transmembrane domains of several MARCH proteins and controls intracellular transport of MARCH proteins. In
addition, we observed that MARCH-VIII reduced the surface expression of the hyaluronic acid-receptor CD44 and both
MARCH-VIII and MARCH-IV sequestered the tetraspanin CD81 in endo-lysosomal vesicles. Moreover, gene knockdown of
MARCH-IV increased surface levels of endogenous CD81 suggesting a constitutive involvement of this family of ubiquitin
ligases in the turnover of tetraspanins. Our data thus suggest a role of MARCH-VIII and MARCH-IV in the regulated turnover
of CD81 and CD44, two ubiquitously expressed, multifunctional proteins.
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Introduction
Ubiquitination plays a key role in regulating many diverse
cellular functions, predominantly by tagging proteins for destruc-
tion via either the proteasome or lysosome. The ubiquitin pathway
consists of ubiquitin itself, a single ubiquitin activating enzyme
(E1), a small number of ubiquitin conjugating enzymes (E2’s), and
a wide variety of ubiquitin ligase enzymes (E3’s). Due to the
limited variability in E1 and E2 enzymes, much of the regulation
of the ubiquitin pathway is carried out by the E3’s [1]. E3 enzymes
provide specificity to the ubiquitin pathway by linking E2 enzymes
with their substrates.
Membrane associated RING-CH (MARCH) proteins, belong to
a family of transmembrane ubiquitin ligases (for a recent review
see: [2]) that was initially discovered when RING-CH proteins
encoded by gamma-2 herpesviruses (KSHV-K3, KSHV-K5,
MHV68-K3) were shown to down-regulate the surface expression
of transmembrane immune-stimulatory host cell proteins, partic-
ularly MHC class I, thus contributing to viral immune evasion
[3,4,5]. Leporipoxviruses encode similar MHC-I down-regulating
proteins which contribute to viral virulence [6,7]. This immunor-
eceptor down-regulation is accomplished by the viral proteins
ubiquitinating lysines in the cytoplasmic tails of their transmem-
brane substrates [8]. In the absence of lysines, tyrosines, serines
and threonines can also be ubiquitinated [9,10]. Essential for
ubiquitination is the RING-CH domain which is structurally
similar to canonical RING-HC and RING-H2 domains [11].
Depending on the intracellular site of ubiquitination the same
target proteins can be either degraded by the proteasome via ER-
associated degradation or ubiquitin-mediated targeting to multi-
vesicular bodies (MVB) followed by lysosomal degradation [12].
The sequence and structural homology of the viral MARCH
proteins to host MARCH family suggested that the viral proteins
were pirated from ancestral host proteins that likely perform
related functions.
Vertebrate MARCH family members fall into distinct classes
according to their sequence relatedness and number of trans-
membrane domains [13]. Structurally most similar to the viral
MARCH proteins, are the two-transmembrane spanning proteins
MARCH-I, -II, -III, -IV, VIII, IX and XI [14,15]. We and others
previously demonstrated that several known target proteins of viral
MARCH homologues can also be targeted by human MARCH
proteins [13,14,16,17]. Additionally, the closely related MARCH-
I and MARCH-VIII were found to ubiquitinate MHC class II, a
protein that is not targeted by any of the viral proteins [18,19].
This ubiquitin-mediated MHC-II turnover via MARCH
proteins seems to play a crucial role in the regulation of
antigen-presentation by dendritic cells, macrophages and B-cells
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15132[20,21,22,23]. However, aside from these studies, relatively few
physiological cellular targets for MARCH proteins have been
identified to date [2].
To identify novel targets for MARCH proteins we previously
adapted a quantitative proteomics-based method termed stable
isotope labeling with amino acids in cell culture (SILAC) [24,25]
and monitored KSHV K5-dependent changes in the plasma
membrane proteome [14]. By comparing the relative abundance
of tryptic peptides identified by mass spectroscopy in membrane
fractions of KSHV-K5 expressing HeLa cells labeled with ‘heavy’
amino acids (C
13/N
15) prior to control cells labeled with ‘light’
(C
12/N
14) amino acids, we were able to identify and independently
confirm several novel substrates for KSHV-K5 [14]. Most notably,
this work was the first indication of viral proteins targeting
activated leukocyte cell adhesion molecule (CD166) and the
interferon-induced anti-viral host cell factor BST2/Tetherin [26].
More recently, SILAC was used to determine changes in the
plasma membrane proteome of B cell lines stably expressing
MARCH-IX [27]. Several novel targets were confirmed by flow
cytometry thus validating this approach to identify cellular
proteins that are targeted by MARCH family proteins.
Based on quantitative membrane proteomics identification of
novel membrane-associated proteins down-regulated by
MARCH-VIII in primary human fibroblasts, we now show that
the ER resident chaperone Bap31 is a binding partner for the
majority of MARCH proteins and that Bap31 controls their
intracellular transport. In addition, we identify two novel targets
for MARCH-VIII. Specifically, show that the hyaluronic acid
receptor CD44 and the tetraspanin CD81 are internalized and
targeted to lysosomes in the presence of MARCH-VIII. CD81
expressed in fibroblasts was additionally targeted by MARCH-IV
since over expression of MARCH-IV redirected CD81 to
lysosomes whereas siRNA treatment against endogenously ex-
pressed MARCH-IV increased CD81 surface levels. Thus, CD44
and CD81 likely represent physiological substrate of MARCH-I
and VIII. CD44 and CD81 perform multiple functions including
the regulation of cell-cell interactions within the immune system
and elsewhere. Our data suggest that these proteins can be
regulated by ubiquitination via MARCH proteins.
Materials and Methods
Reagents
The following antibodies were used: anti-CD44 (clones F-4 and
DF1485) and anti-CD81 (clone 5A6) (Santacruz Biotechnology),
anti-Bap31 (Affinity Bioreagents), anti-TfR (US Biologicals), anti-
Flag (Sigma). Plasmids expressing MARCH cDNA’s have been
described previously [13]. Ad-MARCH-VIII and Ad-K5 have
been described previously [6,14]. Ad-Vpu was a generous gift from
A. Moses (Vaccine and Gene Therapy Institute, OR, USA) [28].
Cells
Human foreskin fibroblasts were obtained from ATCC and
maintained in DMEM (Invitrogen) supplemented with 10% fetal
calf serum (Hyclone) and 16pen/strep.
Stable isotope labeling of HFF cells
Cells were labeled with stable isotopes using labeling medium
(DMEM, Invitrogen) lacking the amino acids L-lysine and L-
leucine (prepared according to the manufacturer’s protocol).
Medium was supplemented with 10% dialyzed fetal calf serum
(Hyclone), 16Pen/Strep (Invitrogen), and either isotopically light
L-lysine and L-leucine (Sigma) or isotopically heavy L-lysine (U-
13C6, 98%; U-15N2, 98%) and L-leucine (U-13C6, 98%; 15N,
98%) (Cambridge Isotope). Cells were maintained in labeling
medium long enough to allow for 6 doublings prior to initiation of
the experiment to ensure complete labeling.
Preparation of samples for MS/MS analysis
Cells grown in labeling medium were infected with either Ad-
Tet + Ad-MARCH-VIII (heavy-labeled cells) or Ad-Tet (light-
labeled cells) alone at an MOI of 200. 24 hrs post-infection, cells
were harvested by scraping, washed twice in PBS, resuspended in
PBS containing 5 mM EDTA, and lysed by douncing. Unlysed
cells and debris were cleared from the lysate by centrifugation for
5 min at 3,0006g. The cleared lysates were separated into
membrane and soluble fractions by centrifugation for 30 min at
45,0006g. The membrane fraction was resuspended in PBS by
sonication and separated over a discontinuous sucrose gradient
(2 M, 1.6 M, 1.25 M, 1.2 M, and 0.8 M) by centrifugation for
2.5 h at 25,000 rpm (Sorvall SW-28 rotor). The bands corre-
sponding to the plasma membrane (0.8–1.2 M interphase), Golgi
(1.2521.2 M interphase), and ER (1.6–1.25 M interphase)
fractions were removed, diluted 56in Tris-EDTA (pH 8.0), and
centrifuged for 30 min at 45,0006g to pellet the proteins
contained in each fraction. Pellets were washed for 30 min in
50 mM sodium bicarbonate (pH 11.5) and centrifuged for 30 min
at 45,0006g, followed by a second wash in 50 mM ammonium
bicarbonate (pH 8.5) and further centrifugation for 30 min at
45,0006g. Final pellets were resuspended in 8.0 M deionized urea
and 50 mM ammonium bicarbonate (pH 8.5) and protein levels
quantitated using the Bio-Rad Protein Assay (Bio-Rad). Samples
were reduced with DTT (Sigma) and alkylated with iodoacetamide
(Sigma) prior to overnight digestion with trypsin (Promega).
Chromatography, MS, and informatics
Peptide mixtures were analyzed by electrospray ionization
tandem MS, coupled to two-dimensional liquid chromatography,
which was performed using a modified version of the protocol
described by Link and coworkers [29]. Briefly, 22 mg of sample
was loaded onto an Opti-Pak capillary SCX trap cartridge
(Optimize Technologies) and eluted stepwise (12.5, 25, 37.5, 50,
62.5, 75, 87.5, 100, 112.5, 125, 200, 300, or 450 mM ammonium
acetate in 0.1% formic acid) onto a reverse phase C-18 capillary
column (180 um6100 mm, BioBasic-18; Thermo Electron).
Peptides were then eluted using an acetonitrile gradient (5%,
5 min; 5%–40%, 75 min; 40%–90%, 10 min) into a ProteomeX
LCQ Deca XP Plus mass spectrometer (Thermo Electron)
equipped with a low-flow (1 ml/min) electrospray source. The
instrument was set to trigger data-dependent MS/MS acquisition
of the three most intense ions detected during the MS survey scan
when total ion current per MS survey scan exceeded 5.0610
5
counts.
Proteins were identified by analyzing tandem mass spectra with
the Sequest algorithm (Thermo Electron) as described [30] using
the human subset of the UniProt/Swiss-Prot protein database
(UniProt release 5.1, http://www.expasy.org/sprot). The search
results were further analyzed using PeptideProphet [31]. SILAC
ratios were determined using the ASAPRatio algorithm [32].
Multiple peptides derived from a single protein were included if
PeptideProphet probability was greater than or equal to 0.85. All
positive results were manually verified.
Real-Time PCR
Short (50–100 bp) fragments from MARCH-I, MARCH-II,
MARCH-IV, MARCH-VIII and MARCH-IX cDNA were
amplified via PCR using appropriate primers. The PCR reaction
was carried out in the following buffer: 16 SYBR Green PCR
Novel Targets of MARCH Proteins
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Amplitaq Gold (PE Biosystems), 0.01 ml Amperase (PE Biosys-
tems), and 50 nM primers. 20 ml buffer was added to 5 ml template
cDNA and run under the following conditions: 95uC for 10 min,
followed by 40 cycles of 95uC for 15 seconds, 60uC for 1 minute.
Amplification was tracked via SYBR-Green (PE Biosystems)
incorporation using an ABI-PRISM 7700 Sequence Detection
System (Applied Biosystems).
Co-immunorecipitation, Western Blot, and Surface
Labeling
Cells were washed twice with PBS and lysed in PBS containing
1% CHAPS (Sigma). Lysates were pre-cleared with protein A/G
agarose beads and incubated with 1 mg of antibody for 1 hr and
followed by 1 hr incubation with protein A/G beads. Immuno-
precipated proteins were washed four times with PBS containing
1% CHAPS. Samples were boiled in SDS buffer and analyzed by
SDS-PAGE gel electrophoresis. For Western blot analysis, SDS-
PAGE gels were transferred to Immobilon-P PVDF membrane
(Millipore) using semidry transfer. Following transfer, membranes
were blocked in 10% milk in PBS +1% tween-20. Membranes
were incubated with primary and secondary antibodies in 5% milk
for 30 minutes. Following each antibody incubation, membranes
were washed 3 times with PBS +1% tween-20, and once with
dH2O.
Surface biotinylation studies were carried out using the Cell
Surface Protein Biotinylation and Purificaiton Kit (Pierce)
according to the manufacturer’s recommendations.
Flow Cytometry
Cells were removed from tissue culture dishes with 0.05%
trypsin-EDTA (Invitrogen), washed with ice-cold PBS, and
incubated with appropriate antibody for 30 min at 4uC. The cells
were washed with ice-cold PBS and either resuspended in ice-cold
PBS or incubated with PE-conjugated anti-mouse secondary
antibody (Dako) and washed again before analysis with a BD
Biosciences FACSCalibur flow cytometer.
Immunofluorescence
HeLa cells were plated on glass cover slips and 24 h later were
transfected with MARCH-FLAG constructs using FuGene
according to manufacturer’s specifications (Roche). After 24 h of
transfection, cells were fixed for 10 min in 2% formaldehyde in
PBS, rinsed twice in PBS, and block with 10% FBS/PBS for
20 min. Cells were incubated with primary antibodies in 10%
FBS/PBS in the presence of 0.2% saponin for 1 h. Cells were
washed 36 with 10% FBS/PBS and incubated with Alexa-dye
conjugated secondary antibodies for 1 h to detect primary
localizations. Cells were washed twice with 10% FBS/PBS, twice
with PBS, and mounted on slides using Fluoromount-G (South-
ernBiotech). All images were obtained using a 510 LSM confocal
microscope (Zeiss) with 636Plan Apo objective. Adobe photoshop
was used for image processing.
siRNA Treatment
Knockdown of Bap31 was accomplished using anti-BCAP-31
(Bap31) siGENOME siRNA (Dharmacon). siRNA transfection
was accomplished using Oligofectamine (Invitrogen) according to
manufacturers recommendations. 25% confluent 35 mm dishes of
HFF’s were treated twice with 5 ml siRNA (20 mM). Treatments
were 6 h apart. Three days post treatment, cells were treated again
with siRNA as described. Cells were analyzed 4 days after the
second siRNA treatment.
Results
Proteomic Analysis of MARCH-VIII-expressing human
fibroblasts
To identify novel substrates for MARCH-VIII proteins in
human cells, we used primary human foreskin fibroblasts (HFF).
These cells were selected for several reasons: 1) HFFs express low
levels of most MARCH proteins, thus allowing validation of
identified targets by siRNA treatment (see below); 2) they are
primary human cells; 3) they grow robustly allowing the five
doublings required for complete incorporation of the stable
isotopes [24,25]. To detect changes in the membrane proteomes
of HFFs upon forced-expression of MARCH-VIII we compared
the abundance of proteins that were metabolically labeled using
stable isotopes and identified by tandem MS/MS. HFFs were
grown in either ‘light’ media containing normal lysine and
leucine, or ‘heavy’ media containing N
15/C
13-labeled leucine and
lysine. To ensure complete labeling, cells were grown in labeling
media for six doublings (,2 weeks). Following metabolic labeling,
‘light’ labeled samples were infected with Adenovirus expressing
the Tetracycline regulatable-transactivator (Ad-Tet) alone, while
‘heavy’ labeled’ samples were infected with Ad-Tet together with
Tet-induced Ad-MARCH-VIII. 24 h post infection, cells were
harvested via mechanical scraping and cellular fractions were
separated as described [14] except that only the plasma
membrane (PM) fraction was analyzed. Following trypsinization,
PM samples were separated with two-dimensional liquid
chromatography (strong cation exchange followed by reverse
phase chromatography) and then analyzed by mass-spectrometry
using a LCQ ion-trap instrument in data-dependent MS/MS
mode. Ion spectra were identified using SEQUEST software and
statistically analyzed using PeptideProphet. To limit false positive
peptide identifications a PeptideProphet cutoff of 0.85 was
applied. To further minimize experimental error and limit false
positive results, three biological replica experiments were
prepared and independently analyzed. Each experiment resulted
in the identification of between 300–500 unique proteins (data
not shown).
To determine proteins whose expression was altered by
MARCH-VIII, ratios between heavy and light peptide peaks
were determined using the ASAPRatio algorithm [32]. Ratios of
individual peptides belonging to the same protein were grouped
together using ProteinProphet to obtain a ratio for the expression
of each identified protein [32]. HFFs express three known
substrates of MARCH-VIII: Transferrin receptor (TfR), MHC
class I, and activated leukocyte adhesion molecule (ALCAM,
CD166) [13,14]. However, we failed to recover peptides
corresponding to TfR or the MHC I heavy chain in any of the
experiments. This is likely due to the lower expression levels of
both TfR and MHC I in HFFs compared to HeLa cells previously
used. In contrast, the light chain of the MHC I heterodimer, b2-
microglobulin (b2m), was recovered in all three experiments
(Table 1). The recovery of b2m but not MHC I heavy chain
might be due to the fact that b2m is non-polymorphic in contrast
to the multiple MHC I alleles present in the mixed population of
primary fibroblasts. Since peptides derived from the known
MARCH-VIII substrate ALCAM were recovered in only two of
the three experiments, we also considered proteins identified in
two out of three experiments as likely targets. Thus, proteins
displaying a ratio in the top or bottom 25% of two of the three
experiments were considered potential candidates if they were
absent from the third experiment due to a failure to recover any
peptides. Using this initial filter resulted in the identification of 13
candidate protein targets for MARCH-VIII (Table 1).
Novel Targets of MARCH Proteins
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abundance upon expression of MARCH-VIII: MARCH-VIII
itself and Grp78/Bip. Grp78/Bip is an ER resident chaperone
that is transcriptionally up-regulated as part of the unfolded
protein response, which is triggered by elevated levels of viral or
cellular proteins in the ER. Therefore, it is likely that up-regulation
of Grp78 is due to the forced expression of MARCH-VIII.
However, this has yet to be confirmed experimentally.
All remaining 11 proteins displayed lower levels in Ad-
MARCH-VIII-transduced cells compared to control cells. Of
these proteins, three were down-regulated in all three experiments:
b2M, CD44, and CD81. Since MHC-I is known to be moderately
down-regulated by MARCH-VIII [13], it is likely that the
observed reduction of b2m, is caused by the removal of MHC-I
from the cell surface. Alternatively, it is conceivable that
MARCH-VIII also down-regulates some of the non-classical
HLA-like molecules that associate with b2m. However, we did not
recover non-classical MHC molecules in any of our experiments.
Since expression levels for both CD44 and CD81 were consistently
lower in the presence of MARCH-VIII in all three experiments,
these molecules represented the most likely candidates for novel
MARCH-VIII substrates. CD44 is a type I transmembrane
glycoprotein that connects a variety of extracellular matrix
proteins, most notably hyaluronic acid (HA), to the cell surface
[33]. CD81 is a member of the tetraspanin family which together
form the ‘tetraspanin-web’ that regulates the lateral localization of
other surface proteins [34].
Proteins down-regulated in two of three experiments were
considered less likely to be true substrates for MARCH-VIII. In
fact, most of the proteins found in this class seemed unlikely targets
for MARCH-VIII due to their predicted subcellular localization in
contaminating fractions of our membrane preparation such as
cytosolic, nuclear or mitochondria (data not shown). However two
proteins, CD9 and Bap31, represented potentially true positives
due to their transmembrane structure and location at the plasma
membrane or intracellular vesicular compartments. Like CD81,
CD9 is a surface glycoprotein of the tetraspannin family. CD9 and
CD81 interact with each other and regulate many of the same
cellular processes [35]. Bap31 is a molecular chaperone that
regulates intracellular trafficking of a number of cell surface
proteins, including tetraspanins as well as MHC-I [36,37,38,39].
Therefore, we included CD9 and Bap31 for further validation
studies.
Bap31, but not CD9 is removed from the cell surface by
MARCH-VIII
To validate the proteomics results, we examined CD9
expression by flow-cytometry in both HeLa cells and HFFs.
However, expression of MARCH-VIII in either cell type did not
result in any down-regulation of CD9 from the cell surface (data
not shown). Thus, the lower levels of CD9-derived peptides
seemed to be a false-positive result caused by inter-experimental
variation.
Unlike ALCAM and CD9, Bap31 is an ER resident chaperone
associated with the forward transport of a wide variety of cell
surface proteins. In addition to MHCI, Bap31was shown to
regulate the intracellular of p450 [40], gamma actin [41],
cellubrevin [42], cystic fibrosis transmembrane conductance
regulator [43], membrane bound IgD [44], CD18 and CD11b
[45] as well as HPV E5 [46]. In addition, Bap31 has been
implicated in retro-translocation during ER-associated protein
degradation [47]. To determine whether MARCH-VIII reduces
Bap31 levels, we initially measured total Bap31 levels in Ad-
MARCH-VIII transduced HFFs by immunoblot. However, total
Bap31 levels were not changed (Fig. 1).
Table 1. Proteins displaying a differential abundance
following MARCH-VIII expression.
Protein Average Ratio Identified in Unique Peptide
Downregulated
B2MG 2.41 3/3 2
CD44 1.70 3/3 6
CD81 3.10 3/3 2
Bap31 2.35 2/3 1
CD166 2.93 2/3 4
CD9 2.43 2/3 3
DAG1 2.81 2/3 1
ECHA 2.51 2/3 1
EGLN 2.29 2/3 2
RALA 3.06 2/3 1
RL15 3.02 2/3 1
Upregulated
MARCH-VIII 0.10 3/3 3
Grp78 0.85 3/3 11
13 proteins displayed a change in abundance of more than 2 fold following
transduction with Ad-MARCH-VIII in two of three replicate experiments. Listed
are the Uniprot designations for each protein, as well as the average ratio
observed. Ratios given are Ad-Tet:Ad-MARCH-VIII. Ratios.1 correspond to
proteins that are downregulated by expression of MARCH-VIII while ratios ,1
correspond to proteins that are upregulated by expression of MARCH-VIII. Also
given are the number of unique peptides used to identify each protein and
whether that protein was changed in 2/3 or 3/3 experiments.
doi:10.1371/journal.pone.0015132.t001
Figure 1. MARCH-VIII reduces surface expression of Bap31.
HFF’s were transduced with Ad-Tet and Ad-MARCH-VIII or Ad-Tet alone.
24 hours post-infection, cells were biotinylated. Prior to purification of
biotinylated proteins, 100 ml of each sample was removed for analysis
of protein expression in each whole cell lysate (WCL). Expression of
Bap31 was analyzed in both the biotinylated fraction and the whole cell
lysate using immunoblot. Expression of MARCH-VIII and the known
MARCH-VIII substrate transferrin receptor (TfR) were included as
controls.
doi:10.1371/journal.pone.0015132.g001
Novel Targets of MARCH Proteins
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15132While most Bap31 is in the ER, a small portion of Bap31 is
present in both the Golgi apparatus and at the plasma membrane
[45,48]. Since our initial proteomic screen showed a reduction of
Bap31 levels in a fraction highly enriched for the plasma
membrane, we hypothesized that expression of MARCH-VIII
might affect the small portion of Bap31 which localizes to the cell
surface. To test this hypothesis, HFFs were infected with Ad-Tet
or Ad-MARCH-VIII and, 24 hours post infection, proteins at the
cell surface were labeled with Biotin using the Cell Surface
Biotinylation and Purification Kit (Pierce). The biotinylated
fraction was then purified according to the manufacturer’s
recommendations. A small portion of each whole cell lysate
(WCL) was removed prior to biotin purification to determine total
Bap31 levels in the lysate. Both biotinylated and WCL fractions
were separated using SDS-PAGE and the levels of MARCH-VIII,
Bap31, and TfR were analyzed by immunoblot (Fig. 1). While the
majority of MARCH-VIII was seen in the WCL fraction,
MARCH-VIII was also present in the biotin fraction. This
suggests that a small portion of MARCH-VIII traffics to the cell
surface. As previously described, a small portion of Bap31 was seen
in the biotin fraction, suggesting a cell surface localization [45].
Interestingly, the levels of biotinylated Bap31 were significantly
reduced following expression of MARCH-VIII. In contrast, total
levels of Bap31 in the WCL fraction remained unchanged whereas
expression of MARCH-VIII strongly reduced levels of TfR in
both the biotinylated and WCL fractions consistent with
previously reported flow data [13]. These data suggested that
MARCH-VIII does not degrade Bap31 localized to the ER, but
either inhibits Bap31 trafficking to the cell surface or degrades
surface expressed Bap31.
Since Bap31 interacts with a wide variety of proteins it was
possible that the reduction of Bap31 surface levels was due to
MARCH-VIII binding to Bap31 in intracellular membrane
compartments. To examine this hypothesis we transfected a
MARCH-VIII expression plasmid into both HeLa cells and HFFs.
24 hours post transfection, cells were lysed in the mild detergent
CHAPS to preserve protein-protein interactions. MARCH-VIII
was immuno-precipitated using an anti-Flag antibody and samples
were separated using SDS-PAGE. Following transfer to PVDF
membrane, the presence of Bap31 in each sample was analyzed by
western blot. A strong signal for Bap31 was observed following
MARCH-VIII immuno-precipitation in HeLa cells transfected
with MARCH-VIII (Fig. 2A). This suggested that Bap31
interacted directly with transfected MARCH-VIII. 5% of each
sample was blotted using anti-Flag antibody to confirm expression
of MARCH-VIII. The failure to observe Bap31 in samples from
transfected HFFs is likely due to low transfection efficiency since
MARCH-VIII was not detected either (data not shown). In
contrast, when MARCH-VIII was expressed by adenovirus
transduction, Bap31 was also clearly present following MARCH-
VIII immune-precipitation from HFF (Fig. 2B). This strongly
suggests that MARCH-VIII interacts directly with Bap31
independent of the cell type.
Since Bap31 interacted with MARCH-VIII, we tested whether
Bap31 would interact with other cellular or viral MARCH-
proteins. Expression plasmids for each construct were transfected
into HeLa cells and then analyzed as above (Fig. 2C). Bap31 was
observed in samples transfected with virtually all MARCH
proteins with the notable exception of MARCH-II despite clearly
detectable MARCH-II expression. Similarly, very little Bap31 was
observed in samples transfected with Vpu, a viral protein
interacting with cellular ubiquitin ligases not related to MARCH
proteins [28]. K5 and MARCH-IX form SDS-stable high
molecular weight complexes so that very little protein correspond-
ing to the predicted molecular weight is recovered (see also
Fig. 2E). Nevertheless, Bap31 was recovered with each of these
proteins. We conclude that Bap31 interacts with most members of
the MARCH-family.
Previous interactions with Bap31 have been shown to be
mediated through the transmembrane domains [39,45]. To
determine if this was true for Bap31’s interactions with the
MARCH proteins we used a series of N- and C-terminal
truncations. Expression plasmids for each truncation were
transfected into HeLa cells. Following immune-precipitation of
each truncation using an anti-Flag antibody, each sample was
analyzed for the presence of Bap31 by immunoblot. Deletion of
the entire C-terminus of either MARCH-VIII (MARCH-VIII 1–
220) or MARCH-IV (MARCH-IV 1–259) had no effect on Bap31
binding (Fig 2D, E). These data suggest that the interaction
between Bap31 and MARCH proteins is not mediated through
the C-terminus. Similarly, deletion of the entire N-terminus of
MARCH-IV (MARCH-IV 89–347) or disruption of the RING-
CH domain through mutational analysis (MARCH-IV C to S) or
addition of the metal chelator EDTA (MARCH-IV + EDTA) did
not prevent the interaction with Bap31. These results suggested
that the N-terminus and RING-CH domain of MARCH proteins
do not mediate the interaction with Bap31. Finally, Bap31 was
also recovered following expression of a construct encoding the
region 89–259 that comprises the zing finger and trans-membrane
domains of MARCH-IV (MARCH-IV 89–259). Despite signifi-
cantly different levels of expression, similar levels of Bap31 were
recovered from cells expressing just the transmembrane domains
of MARCH-IV and from wild-type MARCH-IV. This strongly
argues that Bap31 interacts with the MARCH proteins through
their transmembrane domains.
Bap31 targets MARCH-VIII to the cell surface
Since Bap31 serves as a forward cargo transporter, it was
possible that MARCH proteins require this chaperone for correct
folding and ER exit. To test this hypothesis we depleted HeLa cells
of Bap31 using siRNA followed by transfection with MARCH-
VIII. 24 hours post-transfection, the cell surface was labeled with
biotin and both biotin and WCL fractions were prepared as above.
Following separation using SDS-PAGE, the levels of MARCH-
VIII and Bap31 in each fraction was analyzed via immunoblot
(Fig. 3A). Although only a partial knockdown of Bap31 was
achieved (Fig. 3A, B), the levels of Bap31 present in the
biotinylated fraction were significantly reduced (Fig. 3A Top).
In cells depleted of Bap31, a significantly reduced amount of
MARCH-VIII was observed in the biotinylated fraction. This was
not due to lower overall expression, since similar levels of
MARCH-VIII were observed in the WCL fraction. Surface
expression of B7.2, which is not known to interact with Bap31 was
unaffected (data not shown). Despite knockdown of Bap31, some
MARCH-VIII was still present in the biotinylated fraction. This
might be due to incompletely knockdown of Bap31, since even in
depleted cells Bap31 was still co-immuno-precipitated with
MARCH-VIII (Fig 3B). Presumably due to the remaining
MARCH-VIII, we did not observe an effect of Bap31 knockdown
on the down-regulation of MARCH-VIII target proteins (data not
shown). Taken together these data suggest that Bap31 supports the
intracellular transport of MARCH proteins by intra-membrane
interactions. Due to this interaction, Bap31 remains intracellular
upon forced expression of MARCH proteins which explains its
reduced presence in the plasma-membrane fraction of MARCH-
VIII transduced cells. We conclude that Bap31 plays a role in the
folding, assembly and intracellular transport of MARCH proteins.
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The most likely candidates for novel MARCH-VIII substrates
were CD44 and CD81 since both proteins were present at reduced
amounts in all three biological replicas. To independently confirm
that CD44 and CD81 were down-regulated by MARCH-VIII,
HFFs were transduced with either Ad-Tet or Ad-MARCH-VIII
together with Ad-Tet and expression of CD44 and CD81 was
examined by flow cytometry at 24 h post infection (Fig. 4A).
Samples transduced with Ad-MARCH-VIII (line) displayed a
reduction of both CD44 and CD81 at the cell surface compared to
cells infected with Ad-WT (fill). Downregulation of TfR is shown
as a control.
To compare the steady state levels of CD44 and CD81 in the
presence or absence of MARCH-VIII we used immunoblotting.
HFFs were transduced as above and whole cell lysates were
analyzed via immunoblot using specific antibodies (Fig. 4B). In
samples transduced with Ad-MARCH-VIII, a significant reduc-
tion of both CD44 and CD81 was seen. In contrast, transduction
with adenovirus expressing either KSHV-K5 or HIV-1-Vpu had
no effect on either CD44 or CD81 levels. Equal protein loading
was confirmed by immunoblotting for Bap31 since total levels of
Bap31 do not change upon MARCH expression as discussed
above. Thus, it seems that both CD44 and CD81 are specifically
affected by MARCH-VIII but not by viral MARCH proteins or
unrelated ubiquitin ligases.
Specificity of CD44 and CD81 downregulation by the
MARCH Family
MARCH proteins display specific, but overlapping substrate
specificity [13]. Therefore, we tested whether expression of any
other member of the MARCH-family would down-regulate CD44
or CD81. For these experiments we used HeLa cells since they can
be easily transfected with expression plasmids for each MARCH
protein. A plasmid expressing GFP was co-transfected to track
transfected cells. 24 hours post transfection, cells were harvested
and surface expression of CD44 and CD81 was analyzed using
flow cytometry (Fig. 5A). Shown are the mean florescence
intensities of the GFP+ cells (white line) and GFP- cells (black line)
from the same sample. A significant down-regulation of CD81 was
observed in cells expressing MARCH-IV which also reduced
Figure 2. MARCH-VIII interacts with Bap31 through the transmembrane domains. MARCH-VIII C-Flag was expressed in HeLa cells and HFFs
using either transfection (A) or adenoviral transduction (B). Cells were lysed in 1% CHAPS and MARCH-VIII was immunoprecipitated using the anti-
Flag antibody. Following immunoprecipitation, samples were separated on an SDS-PAGE gel and the presence of Bap31 was analyzed via
immunoblot. 5% of each sample was blotted with anti-Flag antibody to confirm MARCH-VIII expression. (C): HeLa cells were transfected with C-
terminally Flag tagged versions of each MARCH protein as well as the viral MARCH proteins KSHV-K3, KSHV-K5, MYXV-M153 and the HIV-1 protein
Vpu. 24 hours post transfection, each sample was lysed and analyzed as above. Expression of each transfected protein was confirmed by blotting 5%
of each immunoprecipitation with the anti-Flag antibody. (D): To determine which region of MARCH proteins was required for interaction with Bap31
we used a series of previously constructed MARCH -VIII truncations. HeLa cells were transfected with C-terminally flag-tagged versions of truncated
MARCH-VIII. 24 hours post transfection, samples were lysed and analyzed as above. (E): Similar experiments were performed with truncated MARCH-
IV (right panel). Bap31 failed to coimmunoprecipitate following the removal of the entire C-terminus of MARCH-VIII (1–220) or MARCH-IV (1–259),
removal of the entire N-terminus of MARCH-IV (89–347) or disruption of the MARCH-IV RING-CH domain by either mutation (MARCH-IV C to S) or
addition of EDTA.
doi:10.1371/journal.pone.0015132.g002
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surprising since the closest homologue of MARCH-VIII is not
MARCH-IV, but MARCH-I which demonstrated almost identi-
cal substrate specificity to MARCH-VIII in previous experiments
by us and others [13,18,19].
To determine whether reduced surface levels of CD81 and
CD44 were due to degradation or redistribution of these proteins
by MARCH-VIII and MARCH-IV we performed immune-
fluorescence analysis (IFA). HeLa cells were transfected with each
of the Flag-tagged MARCH proteins and co-stained with
antibodies for Flag and CD44 (Fig. 5B) or CD81 (Fig. 5C).
Both CD44 and CD81 were absent from cells transfected with
MARCH-VIII (in red). In contrast, neighboring cells that were
negative for MARCH-VIII were brightly labeled with CD44 or
CD81 antibodies (in green). CD81 was also absent from cells
transfected with MARCH-IV whereas CD44 was unaffected
suggesting that MARCH-IV has only a minimal impact on CD44.
Consistent with the flow-cytometry results, all other MARCH
proteins did not affect expression levels of CD44 and CD81. These
data suggest that CD81 is degraded by both MARCH-IV and
MARCH-VIII whereas CD44 is degraded by MARCH-VIII.
Lysosomal targeting of CD44 and CD81
Most proteins ubiquitinated by MARCH proteins are internal-
ized and targeted for lysosomal degradation via the multi-vesicular
body pathway [18]. To determine whether CD81 and CD44 were
degraded in lysosomes we performed IFA in the presence of
NH4Cl which inhibits endosomal maturation. As shown in
Fig. 6A, CD81 was found in distinct punctate structures upon
NH4Cl-treatment in the presence of MARCH-IV or MARCH-
VIII whereas CD81 remained at the cell surface in MARCH-I-
transfectants. A similar distribution was observed for CD44 in the
presence of MARCH-VIII, but not MARCH-IV. To determine
whether the vesicles containing CD81 and CD44 in the presence
of MARCH proteins represented late endosomes or lysosomes we
co-stained CD81 and CD44 in MARCH-transfected cells with the
lysosomal marker Lamp-1. In cells expressing MARCH-VIII and
MARCH-IV (Fig. 6B, labeled with *), CD81 (in green) partially
Figure 3. Depletion of Bap31 reduces surface expression of MARCH-VIII. HeLa cells were depleted of Bap31 using siRNA as described in the
materials and methods section. (A): Following Bap31 depletion, HeLa cells were transfected with a plasmid expressing MARCH-VIII. 24 hours post
transfection cells were biotinylated. Following separation via SDS-PAGE gels, surface expression (Top) or total expression (Bottom) of both Bap31 and
MARCH-VIII were analyzed via immunoblot. Cells depleted of Bap31 show reduced surface expression of both Bap31 and MARCH-VIII. (B): Depletion
of Bap31 also reduced the levels of Bap31 associated with MARCH-VIII. Following Bap31 depletion, HeLa cells were transfected with a plasmid
expressing MARCH-VIII. 24 hours post transfection cells were lysed in 1% CHAPS and MARCH-VIII was immunoprecipitated using an anti-Flag
antibody. Samples were separated via SDS-PAGE and the presence of Bap31 determined by immunoblot (B Top). Expression of Bap31 and MARCH-VIII
were confirmed in whole cell lysates (B Bottom).
doi:10.1371/journal.pone.0015132.g003
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observed in neighboring untransfected cells. A similar co-staining
was observed for CD44 upon transfection of MARCH-VIII
(Fig. 6B). Therefore, we conclude that CD81 is targeted for
lysosomal destruction by MARCH-IV and MARCH-VIII
whereas CD44 is directed to lysosoaml degradation only by
MARCH-VIII.
Knockdown of MARCH-IV results in upregulation of CD81
Since HHFs express detectable levels of endogenous MARCH-
VIII and MARCH-IV (Fig. 7A), we wondered whether the steady
state level of CD44 or CD81 was affected by the constitutive,
albeit low level expression of these ubiquitin ligases. Therefore,
HFFs were treated with siRNA against both MARCH proteins
either separately or in combination. Knockdown of each MARCH
protein was confirmed by real time PCR (Fig. 7B). Treatment
with either MARCH-IV or MARCH-VIII siRNA reduced
corresponding MARCH RNA levels by around 90%. RNA levels
for MARCH-IV or MARCH-VIII were unchanged by treatment
with the mismatched siRNA, showing that depletion was sequence
specific. Additionally, treatment with a siRNA against MARCH-I
had no effect on RNA levels for either MARCH-IV or MARCH-
VIII. Since MARCH-I is not expressed in HFF cells (data not
shown) this served as a control. Following depletion of MARCH-
IV or MARCH-VIII, cells were harvested and the surface levels of
CD44 and CD81 were measured using flow-cytometry. Treatment
with siRNA against either MARCH-IV or MARCH-VIII showed
no effect on the surface levels of CD44 (Fig. 7C). Similarly, CD81
levels did not change upon MARCH-VIII knockdown. In
contrast, treatment with siRNA against MARCH-IV resulted in
a 50% increase of CD81 surface levels compared to either
untreated cells or cells treated with other siRNA (Fig. 7C). While
modest, this increase was reproducible over five separate
experiments and statistically significant with a p value,0.01
compared to treatment with siRNA against MARCH-VII. This
increase was not due to increased transcription of CD81 since
treatment with MARCH-siRNAs did not increase levels of CD81
mRNA (Fig. 7B). Co-transfection of siRNA against MARCH-IV
and MARCH-VIII did not further increase CD81 levels
suggesting that endogenous MARCH-VIII might be expressed
at levels that are too low to influence CD81 expression whereas
MARCH-IV is more highly expressed as indicated by qPCR
(Fig. 7A). However, endogenous expression levels seem to be too
low for both MARCH proteins to influence CD44 turnover. It
remains to be demonstrated whether CD44 and CD81 are
regulated by MARCH-VIII in cells expressing higher levels of
MARCH-VIII such as immature dendritic cells. However, these
data clearly show that endogenous MARCH-IV constitutively
affects CD81 levels.
Discussion
The goal of this study was to use an unbiased proteomics
approach to identify cell surface proteins regulated by transmem-
brane ubiquitin ligases of the MARCH protein family. Using the
viral MARCH homologue KSHV-K5, we had previously
demonstrated that it is possible to identify novel targets for both
the protein used in the proteomics study, as well as other members
Figure 4. CD44 and CD81 are differentially expressed following MARCH-VIII expression. (A): To confirm that CD44 and CD81 were
removed from the cell surface, HFF’s were infected as above. 24 hours post-infection cells were harvested and processed for flow cytometry. Samples
transduced with Ad-MARCH-VIII (line) display reduced surface expression of CD44 and CD81 compared to samples infected with Ad-Tet alone (fill).
Expression of MARCH-VIII was confirmed by surface staining for the known MARCH-VIII substrate TfR. (B): HFFs were transduced with Ad-WT, Ad-K5,
Ad-Vpu, or Ad-MARCH-VIII. 24 hours post-transduction cells were harvested and whole cell lysates were analyzed for the abundance of CD44 and
CD81 using immunoblot. Samples infected with Ad-MARCH-VIII display significantly reduced levels of both CD44 and CD81 compared to either Mock
infected samples or samples infected with other control adenoviruses. Equal protein loading was confirmed by immunoblotting for the ER resident
chaperone Bap31 as well as ponceau red staining.
doi:10.1371/journal.pone.0015132.g004
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were identified as novel substrates for KSHV-K5. Follow up
experiments, however, demonstrated that ALCAM was also
down-regulated by MARCH-VIII and Myxomavirus M153R
whereas BST2/Tetherin was also down-regulated by MARCH-
VIII and HIV-1 Vpu. Similarly, we now show that CD81 was also
down-regulated by MARCH-IV. Although a modest downregu-
lation of CD44 was observed with MARCH-IV by flow cytometry,
this was not observed by IFA. Interestingly, expression of CD44 or
CD81 was not affected by the viral MARCH proteins tested,
suggesting that these endogenous substrates are specifically
targeted cellular MARCH proteins. Also surprising was the
observation that MARCH-I and MARCH-IX, which are closely
related to MARCH-VIII and MARCH-IV, respectively, did not
affect either CD81 or CD44. This is in contrast to our previous
observations which showed that sequence homology strongly
correlated with substrate specificity. Why a similar correlation is
not observed for CD81 and CD44 is presently not known.
While both CD44 and CD81 are widely expressed on different
cell types, their regulation has been shown to play a particularly
important role in the developing immune system. Like most targets
of MARCH proteins, CD44 is a type I transmembrane
glycoprotein. CD44 occurs in many splice variants and connects
a variety of extracellular matrix proteins, most notably hyaluronic
acid (HA), to the cell surface [33]. CD44 plays a crucial role in
inflammation [49] and in cancer progression [50]. It is also
involved in leukocyte recruitment [51] and regulates T cell
interactions during T cell development [52]. Since CD44 exists in
many isoforms and is extensively spliced [53], MARCH-VIII
dependent down-regulation might be variant-specific. However,
this possibility has yet to be investigated. Although elimination of
MARCH-VIII from fibroblasts did not change the steady state
levels of CD44, it is likely that CD44 is affected in more dynamic
situations where MARCH proteins are regulated, such as during
dendritic cell maturation [54]. MARCH- VIII could also play a
role for the HA-induced endocytosis of CD44 and its subsequent
targeting to the multi-vesicular bodies (MVB) [55] since most
MARCH-VIII targets reach the MVB [13,16].
In contrast to CD44, CD81 surface levels were increased upon
depletion of MARCH-IV, suggesting that MARCH-IV is involved
in the natural turnover of CD81 in fibroblasts. While depletion of
MARCH-VIII had no effect on CD81 levels in fibroblasts, it is
possible that higher MARCH-VIII levels in other cell types or
tissues might affect CD81. Unlike most MARCH-targets, which
are single-span transmembrane proteins, CD81 belongs to the
tetraspanin family, four-transmembrane proteins that form the
tetraspanin-web as a membrane microdomain which laterally
incorporates multiple transmembrane proteins [56]. Since several
of the CD81-interacting proteins have been shown to be down-
regulated by MARCH-IV or MARCH-VIII it is possible that
CD81 surface expression is indirectly affected via these bona-fide
targets. Alternatively, it is conceivable that some of these proteins
could be down-regulated as a consequence of CD81 ubiquitination
and degradation. In fact, targeting a protein with widespread
protein:protein interactions, such as CD81, might explain how
MARCH proteins down-regulate such a variety of substrates, with
Figure 5. Downregulation of CD44 and CD81 by other members of the MARCH-family. HeLa cells were transfected with plasmids
expressing cDNAs for each MARCH protein and the surface expression of CD81 and CD44 were assayed by flow cytometry (A) or confocal immune
fluorescence analysis (B and C).
doi:10.1371/journal.pone.0015132.g005
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lacking a functional RING-CH domain and mutants of MARCH-
VIII which are unable to down-regulate B7.2 both fail to down-
regulate CD81 are consistent with either model, further work is
required to distinguish between these possibilities. The validation
of both CD81 and CD44 by independent methods confirms our
previous conclusion that three biological replica experiments give
a high level of confidence for the specificity of the results [14].
Since ALCAM, a known substrate of MARCH-VIII, was
identified in only two of the three experiments, however, we
selected two additional potential candidate proteins, CD9 and
Bap31, for validation based on their sub-cellular localization as
well as their known interaction with MARCH-VIII substrates.
Only Bap31, however, confirmed using independent methods,
indicating that the false-positive rate is high in these types of
experiments when biological replicas are limited. This is primarily
due to the inaccuracy of quantitation using the mass spectroscope.
Unlike CD44 and CD81, steady state levels of Bap31 were not
diminished following expression of MARCH-VIII. Instead, we
found that MARCH-VIII bound to Bap31 and prevented Bap31
from reaching the cell surface. We further observed that Bap31
interacts with most MARCH proteins, suggesting that Bap31
chaperones the folding, assembly or intracellular transport of this
protein family. Interestingly, depletion of Bap31 resulted in lower
amounts of MARCH-VIII expressed on the cell surface. Since
Bap31 is known to function as a forward cargo molecule for
several other proteins [37,39,42,44] we conclude that that Bap31
is involved in sub-cellular sorting of MARCH proteins. Interest-
ingly, the MARCH-family and their viral homologues have been
shown to interact with several other intracellular trafficking
molecules. Depletion of PACS2 inhibited K5 mediated degrada-
tion of newly synthesized CD31, suggesting that it played a key
role in K5 function [12]. Several members of the MARCH-family
have been shown to interact directly with members of the syntaxin
family of SNARE proteins [14,57,58]. However, the functional
consequences of these interactions are not currently understood.
Truncated versions of MARCH-VIII that do not interact with
syntaxins are still able to interact with Bap31 [14] suggesting that
the interaction with Bap31 occurs in the transmembrane region.
This is consistent with previous findings that Bap31’s interaction
with MHC I, IgD, cellubrevin, and p450 localizes to the
transmembrane domains [40,42,44]. Interestingly, expression of
Figure 6. CD81 and CD44 are targeted to lysosomes by MARCH proteins. Flag-tagged MARCH-constructs were transfected into HeLa cells
and the cells were treated with 25 mM NH4Cl for 2 h. Cells were fixed and stained with anti-Flag and anti-CD81 or anti-CD44 antibodies (A) or stained
with either CD81 or anti-CD44 antibodies along with rabbit anti-Lamp1 (B) as described in Materials and Methods. Mouse antibodies were detected
with anti-mouse Alexa 488 (green) and rabbit antibodies with anti-rabbit Alexa 594 (red). In B, MARCH-expressing cells, inferred by the altered
distribution of CD81 and CD44, are indicated with an asterisk (*). Bar, 10 mm (B).
doi:10.1371/journal.pone.0015132.g006
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inhibition of Bap31 might play some role in MARCH-IV and –
VIII down-regulation of CD81.
While depletion of Bap31 affected intracellular transport of
MARCH-VIII, it did not prevent MARCH-VIII-mediated down-
regulation of transfected CD86 (B7.2) (data not shown). This
result, however, is most likely explained by insufficient knockdown
of Bap31, resulting in sufficient amounts of MARCH-VIII
available at the cell surface to ubiquitinate its substrates.
In summary, we present a systematic identification of
endogenous substrates for the MARCH gene family. By using
this non-biased approach to substrate discovery, we further
demonstrate that the tetraspanin CD81 is down-regulated by
both MARCH-IV and –VIII thus expanding the structural range
of possible MARCH substrates. We were also able to show that
depletion of endogenous MARCH-IV increased the surface
expression of CD81, the first time that a substrate of MARCH-
IV has been affected by depletion of endogenous protein. Thus,
these approaches will be useful in unraveling the function of this
class of proteins.
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